Mural Oncology plc - Ordinary Shares
Share · IE000LK2BOB4 · MURA (XNAS)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Mural Oncology plc - Ordinary Shares
No Price
Company Profile for Mural Oncology plc - Ordinary Shares Share
Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.
Company Data
Name Mural Oncology plc - Ordinary Shares
Company Mural Oncology plc
Symbol MURA
Website
https://www.muraloncology.com
Primary Exchange 
NASDAQ
NASDAQ
ISIN IE000LK2BOB4
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Caroline J. Loew
Market Capitalization 35 Mio
Country Ireland
Currency USD
Employees 0,1 T
Address 10 Earlsfort Terrace, D02 T380 Dublin
IPO Date 2023-11-16
ID Changes
| Date | From | To |
|---|---|---|
| 16.11.2023 | MURAV | MURA |
Ticker Symbols
| Name | Symbol |
|---|---|
| NASDAQ | MURA |
More Shares
Investors who hold Mural Oncology plc - Ordinary Shares also have the following shares in their portfolio:
